Cradle, a leader in AI-powered protein engineering, raised $73 million in Series B funding led by IVP, with participation from existing investors Index Ventures and Kindred Capital. This funding brings Cradle's total investment to over $100 million and aims to expand its mission of enabling millions of scientists to develop sustainable products and better therapeutics more efficiently and cost-effectively.
Cradle's platform uses Generative AI to accelerate the discovery and development of proteins, reducing the experimental rounds required and saving significant time and resources. Industry leaders such as Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis, and Grifols use Cradle's technology for applications across therapeutics, diagnostics, food, agriculture, and chemical industries. Results show up to a 12x acceleration in R&D and cost reductions of up to 90%.
The new funding will support the expansion of Cradle's wet lab to enhance its proprietary datasets, further development of its machine learning capabilities for complex protein engineering, and scaling go-to-market operations to reach more scientific teams globally. Cradle ensures customer data security, allowing clients to retain all intellectual property and providing tailored AI models based solely on their data.
Cradle has rapidly grown its customer base and impact, with its AI platform helping unlock stalled projects and significantly improving success rates. The company's approach builds on generative protein language models trained on billions of sequences and refined through continuous feedback from experimental results, enabling iterative improvements.
With applications spanning from sustainable materials to advanced therapeutics, Cradle's platform is reshaping the landscape of protein engineering.